在土耳其2型糖尿病患者中对TNF-α (-308) 基因多态性的比较分析,该患者患有病和/或神经病变
Venhar Gurbuz Can1, Ozlem Cesur Gunay2, Sinem Cesur3
1Department of Medical Biology, Karabuk University Faculty of Medicine, Karabük, 78050, Turkey. venhargurbuz@karabuk.edu.tr.
Scientific reports
|December 31, 2024
概括
这项研究研究了2型糖尿病患者的TNF-alpha (-308) 基因多态性,这些患者患有病或神经病变. 这种基因多态化与患上这些并发症的风险之间没有发现显著的关联.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 是一个遗传学.
- 代谢疾病 代谢疾病
背景情况:
- 2型糖尿病 (T2DM) 是一种慢性代谢性疾病.
- 糖尿病病 (NP) 和神经病 (NR) 是严重的并发症,影响患者的生活质量.
- 在T2DM并发症中TNF-α基因多态性的作用需要进一步调查.
研究的目的:
- 检查TNF-alpha (-308) 基因多态化与T2DM患者NP和NR的风险之间的关联.
- 确定TNF-alpha (-308) 基因多态性是否与NP和/或NR的T2DM患者的人口和生化参数相关.
主要方法:
- 采集血液样本进行DNA分离.
- 使用光探针进行实时PCR用于TNF-α (-308) 基因定型.
- 人口和生化数据被收集和分析.
主要成果:
- 在患者组之间没有观察到TNF-alpha (-308) 基因多态性的A等位基因频率的显著差异.
- 在GG,GA和AA基因型之间没有检测到生物化学参数的显著差异.
结论:
- 在2型糖尿病患者中,TNF-alpha (-308) 基因多态性似乎与脏病或神经病变的风险没有显著的关联.
- 这种多态性与研究的T2DM患者队列中的人口统计或生化特征没有相关.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...


